

03 February 2026

## **Treatment of Chronic Lymphocytic Leukaemia (CLL)**

I refer to your Freedom of Information (FOI) request received on 26<sup>th</sup> January 2026. Outlined below is Belfast Trust's response, which I hope you find helpful.

**Q1. How many patients has your Trust treated in the past 12 months (January - December 2025) for Chronic Lymphocytic Leukaemia (CLL)? In case you do not treat CLL, which other Trust do you refer patients needing treatment to?**

During the 12 month period (1<sup>st</sup> January 2025 to 31<sup>st</sup> December 2025) Belfast Trust treated a total of 96 patients for Chronic Lymphocytic Leukaemia (CLL).

Notes:-

This is based on the patient having a primary diagnosis of ICD10 code C91.1. This data is collated from EPIC choosing hospital admissions by Department Specialty and Primary Coded Diagnosis. This data has not been officially verified.

**Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated by the Trust in the past 6 months on the following treatments:**

- **BR (bendamustine + rituximab)**
- **Brukisa (zanubrutinib)**
- **Calquence (acalabrutinib)**
- **Calquence (acalabrutinib) + Gazyva (obinutuzumab)**
- **Calquence (acalabrutinib) + Venclyxto (venetoclax)**
- **Calquence (acalabrutinib) + Venclyxto (venetoclax) + Gazyva (obinutuzumab)**
- **FCR (fludarabine + cyclophosphamide + rituximab)**
- **Fludarabine Monotherapy**
- **Gazyva (obinutuzumab) + chlorambucil**
- **Imbruvica (ibrutinib)**
- **Venclyxto (venetoclax)**
- **Venclyxto (venetoclax) + Gazyva (obinutuzumab)**
- **Venclyxto (venetoclax) + rituximab**
- **Zydelig (idelalisib) + rituximab**
- **Imbruvica (ibrutinib) + Venclyxto (venetoclax)**
- **Any other systemic anti-cancer therapy**

Belfast Trust does not hold this information centrally. To retrieve it would require a manual trawl through Pharmacy records, which would take more than 18 hours. This would exceed the costs limit specified in the FOI act.

**03 February 2026**

We estimate that compliance with this element of the request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

**Q3. How many Chronic Lymphocytic Leukaemia (CLL) patients have received treatment for relapsed/refractory CLL in the past 6 months with the following:**

- **Brukinsa (zanubrutinib)**
- **Calquence (acalabrutinib)**
- **Imbruvica (ibrutinib)**
- **Venclyxto (venetoclax)**
- **Zydelig (idelalisib) + rituximab**
- **Any other systemic anti-cancer therapy**

Belfast Trust does not hold this information centrally. To retrieve it would require a manual trawl through Pharmacy records, which would take more than 18 hours.

**Q4. If your Trust does treat Chronic Lymphocytic Leukaemia patients, do you currently participate in any ongoing clinical trials for the treatment of CLL? If yes, please can you provide details of the ongoing trials.**

Stellar A phase II, randomised study of CHOP-R in combination with acalabrutinib compared to CHOP-R in patients with newly diagnosed Richter's Syndrome and a platform for initial investigations into activity of novel treatments in relapsed/refractory and newly diagnosed Richter's Syndrome	Open to recruitment
Flair Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab	Close to recruitment, some patients still on treatment
Static A Randomised Phase III Trial Comparing Intermittent with Continuous Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL)	In Set-up